Arbutus Biopharma Corp

ABUS

$5.12

-0.10%

2026-09-04 09:37:12 EDT-$0.00

Healthcare

Biotechnology

NASDAQ

Active Trading

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus ...

Price Action of ABUS

$5.12

-0.10%+$0.00

High—

Low—

52W High-6.1%

Rel. vol—

Interval

Range7m

Volume—SMA5SMA10

—

Key Metrics of ABUS

Snapshot

Latest / TTM · 6 periods

Market Cap

$1.01B

ROCE

54.4%

EV / EBITDA

6.50x

+84.9% YoY

FCF Yield

-2.4%

+1.9% YoY

Cash Conversion Cycle

-31161.7d

Current Ratio

81.42

Quick take

Financial Highlights of ABUS

Profitability trend

Latest / TTM · 6 periods

Gross Margin

100.0%

Net Margin

84.2%

P/E Ratio

6.48x

n/a

Debt / Equity

0.01

n/a

Current Ratio

81.42

Dividend Yield

0.0%

Understanding

Calendar of ABUS

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.02 · Revenue $1.00M · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.02 · Revenue $1.00M · 1 analysts

Financial Statements of ABUS

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
The total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).

Insider Transactions of ABUS

Acquisitions (A)

Since Mar 31, 2025

Disposals (D)

Since Mar 31, 2025

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Leadership Team of ABUS

4 executives

Name	Title	Compensation	Gender	Year Born	Status
Lindsay Androski	President, Chief Executive Officer & Chairman	USD 736,559	Female	1977	Active
Tuan Nguyen	Chief Financial Officer	USD 651,897

GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced the launch of Invenia™ ABUS (Automated Breast Ultrasound) Prime and ABUS StreamVue™, a redesigned enterprise viewer that recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, expanding its breast imaging portfolio with solutions designed to support supplemental screening for women with dense breasts and provide more flexible enterprise-wide exam review. Together, these new solutions aim to help breast i.

Historical Employee Count of ABUS

Current

Change

-56.82%

Minimum

Maximum

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.17 vs -0.19	+9.5%	-0.03 vs -0.02	-50.0%
Revenue Surprise	$14.1M vs $13.6M	+3.3%	$1.0M vs $700000	+44.9%

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	19	10-K	Mar 23, 2026	View
Dec 31, 2024	44	10-K	Mar 27, 2025	View
Dec 31, 2023	73	10-K	Mar 5, 2024	View
Dec 31, 2022	96	10-K	Mar 2, 2023	View
Dec 31, 2021	85	10-K	Mar 3, 2022	View

Date	Executive	Title	Security	Side	Shares	Price
Jun 8, 2026	Sawhney Roger	director	Stock Option (Right to Buy)	A	78,800	$4.24
Jun 8, 2026	Beardsley Robert A	director	Stock Option (Right to Buy)	A	78,800	$4.24
Feb 2, 2026	Nguyen Tuan	officer: Chief Financial Officer	Stock Option (Right to Buy)	A	188,400	$4.39
Feb 2, 2026	Nguyen Tuan	officer: Chief Financial Officer	Common Shares	A	73,500	—
Feb 2, 2026	Androski Lindsay	director, officer: President and CEO	Stock Option (Right to Buy)	A	71,700	$4.39

Arbutus Biopharma Corp

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue

Related stocksBiotechnology

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus Biopharma: Moderna Validates My IP Bull Case

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

FY2026 · Estimated annual results

Q1 FY2027 · Estimated results

Recent history

Q2 FY2026 · Results reported

Q1 FY2026 · Results reported

FY2025 · Annual results

Q3 FY2025 · Results reported

Q2 FY2025 · Results reported

Q1 FY2025 · Results reported

Recent Filings